Findings

What do systematic reviews say?

349 questions · 364 findings · 37 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 96 · 26.4%GRADE not reported 8 · 2.2%Very low 105 · 28.8%Low 94 · 25.8%Moderate 46 · 12.6%High 15 · 4.1%

Antidepressants vs placebo according to any definition

Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence

1 finding from 1 review

Pharmacological treatment for depression during opioid agonist treatment for opioid dependence 2010 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 346 participants
Low

Antidepressants vs placebo

Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence

Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for depression during opioid agonist treatment for opioid dependence 2010 · Cochrane Headline outcomes only
RR 2.03 [1.17, 3.53]
1 study · 137 participants
Low

Antidepressants vs placebo

> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence

Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for depression during opioid agonist treatment for opioid dependence 2010 · Cochrane Headline outcomes only
RR 0.96 [0.54, 1.71]
1 study · 95 participants
Low

Antidepressants plus benzodiazepines vs antidepressants alone

Depression severity ‐ mean EPDS score (early phase, < 5 weeks) · patients with major depression

1 finding from 1 review

Antidepressants plus benzodiazepines for adults with major depression 2019 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 598 participants
Moderate

Antidepressants plus benzodiazepines vs antidepressants alone

Depression severity (acute phase, 5 ≤ 12 weeks) · patients with major depression

1 finding from 1 review

Antidepressants plus benzodiazepines for adults with major depression 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 347 participants
Low

Antidepressants plus benzodiazepines vs antidepressants alone

Depression severity: continuous phase (> 12 weeks) · patients with major depression

1 finding from 1 review

Antidepressants plus benzodiazepines for adults with major depression 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 431 participants
High

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Low

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 199 participants
Moderate

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Moderate

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 808 participants
High

Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 977 participants
High

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Depressive symptoms · treatment‐resistant depression in adults

2 findings from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low
Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Tricylic antidepressant vs placebo

Change in depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Antidepressants vs placebo

Depression at endpoint · patients with depression and dementia

1 finding from 1 review

Antidepressants for treating depression in dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 614 participants
High

Antidepressants vs antidepressants

Clinical response · adults with psychotic depression

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Antidepressants vs antidepressants

Leaving the study early · adults with psychotic depression

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Antidepressants vs antidepressants

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs antidepressants

Acceptability ‐ dropouts due to adverse effects · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Second generation antidepressant vs placebo medication

Depressive disorder according to DSM or ICD criteriaClinician diagnostic interview · patients with depressive disorders in children and adolescents

1 finding from 1 review

Newer generation antidepressants for depressive disorders in children and adolescents 2012 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported